Fujisawa Synthelabo Established In Taiwan
Franco-Japanese joint venture Fujisawa Synthelabo has been set up in Taiwan by Synthelabo, which has a 51% stake, and Fujisawa, which has a 49% holding in the company. The two companies established a similar joint venture in Japan in 1985.
Based in Taipei, the company will import and sell pharmaceuticals produced by Synthelabo and marketed by Fujisawa Taiwan and another company in Taiwan. Its market capitalization is NT$5 million ($180,650). The chairman of the joint venture is Jean-Pierre Fere, general manager of Synthelabo Pharmaceuticals, the vice chairman is T Tsuji, executive director of Fujisawa's international division, and the general manager is H Kikuchi, general manager of Fujisawa Taiwan.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze